Figure 5.

Effect of rIL-6, DAPT and Maritoclax on MAP viability. (A): MAP viability was measured following treatment with rIL-6 (0–500 U/mL) in infected macrophages. (B): MAP viability was measured in infected macrophages which were treated with DAPT (30 μM) then with rIL-6 (0–500 U/mL). (C) MAP viability was measured in infected macrophages which were treated with Maritoclax (0-80 μM). MAP viability was measured using Live/Dead^TM Baclight^TM bacterial viability assay and represented as (CFU/mL). All experiments were performed in triplets. Data are shown as mean ± SD, and significance is considered as * p < 0.05.